Mannkind Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
11.2%projected annual EPS growth
Analyst Coverage
8analysts covering
FY Revenue (est.)
$443.4Mnext fiscal year
FY EPS (est.)
$0.03next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 4 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Total Revenues Quarterly90.2M
Furoscix Net Sales Quarterly15.5MTarget: 110000000 to 120000000
Afrezza Net Sales Quarterly32.7M
Royalties from Collaborations (Tyvaso DPI) Quarterly32.7M
Watch Items
- Furoscix ReadyFlow Autoinjector FDA ApprovalTrigger: PDUFA target action date of July 26, 2026Action: Monitor FDA decision and prepare for commercial launch in Q3 2026
- Nintedanib DPI (MNKD-201) Clinical ProgressTrigger: First patient enrolled in Phase 2 INFLO-2 trial in Q2 2026Action: Track enrollment progress and monitor Phase 1b INFLO-1 topline data expected in 2H 2026
- Afrezza Pediatric Launch ExecutionTrigger: FDA approval received on May 29, 2026 for children aged 6 and olderAction: Evaluate commercial uptake, field team alignment, and pediatric endocrinologist education efforts
Research as of 20 Jun 2026